keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis definition

keyword
https://www.readbyqxmd.com/read/29652832/sympathetic-nerve-hyperactivity-in-the-spleen-causal-for-nonpathogenic-driven-chronic-immune-mediated-inflammatory-diseases-imids
#1
REVIEW
Denise L Bellinger, Dianne Lorton
Immune-Mediated Inflammatory Diseases (IMIDs) is a descriptive term coined for an eclectic group of diseases or conditions that share common inflammatory pathways, and for which there is no definitive etiology. IMIDs affect the elderly most severely, with many older individuals having two or more IMIDs. These diseases include, but are not limited to, type-1 diabetes, obesity, hypertension, chronic pulmonary disease, coronary heart disease, inflammatory bowel disease, and autoimmunity, such as rheumatoid arthritis (RA), Sjőgren's syndrome, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and multiple sclerosis...
April 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29566966/considerations-for-the-definition-of-remission-criteria-in-psoriatic-arthritis
#2
REVIEW
Philip J Mease, Laura C Coates
OBJECTIVES: Psoriatic arthritis (PsA) is an autoimmune disease that can cause progressive structural damage of the joints and irreversible disability. The potentially achievable results of biologic therapy for PsA has led to the view that disease remission should be the goal of treatment. However, the heterogeneity of disease manifestations and need for validated outcome measures makes defining remission in PsA challenging. This article evaluates proposed criteria for defining remission in PsA and discusses how these criteria can be applied in clinical practice...
October 31, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29502473/defining-and-treating-moderate-plaque-psoriasis-a-dermatologist-survey
#3
Melissa L F Knuckles, Eugenia Levi, Jennifer Soung
PURPOSE: Patients with moderate plaque psoriasis are often undertreated and may experience unsatisfactory clinical outcomes. Undertreatment may stem partly from a lack of consensus on the definition of moderate psoriasis and appropriate treatments for patients with moderate disease severity. MATERIALS AND METHODS: An online survey was conducted during October 2015 to determine how US dermatologists in the clinical setting define and treat moderate psoriasis. RESULTS: A total of 150 dermatologists responded to the survey (mean time in practice: 13...
March 5, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29493005/use-of-topical-therapies-for-pediatric-psoriasis-a-systematic-review
#4
REVIEW
Georgios Kravvas, Karolina Gholam
Psoriasis is one of the most common chronic skin diseases, affecting 1%-3% of the general population. It can have a significant negative impact on a patient's quality of life, and in approximately 30% of patients first symptoms can be traced back to childhood. We have performed a comprehensive literature search using the MEDLINE database in order to ascertain the efficacy and adverse reactions of topical treatments in pediatric psoriasis. A total of 13 relevant articles were identified on the following topical agents: corticosteroids, calcineurin inhibitors, vitamin D analogs, and dithranol...
March 1, 2018: Pediatric Dermatology
https://www.readbyqxmd.com/read/29482382/guselkumab-for-the-treatment-of-psoriasis
#5
Matteo Megna, Anna Balato, Annunziata Raimondo, Nicola Balato
Psoriasis is a chronic immune mediated disease in which the interplay of T cells and keratinocytes seems to play a key role. In this context, the interleukin (IL)-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis and the selective inhibition of IL-23 may be viewed as an improvement of treatments blocking both IL-23 and IL-12, since its upstream actions. Areas covered: The authors performed a thorough and updated review on guselkumab, a fully human IgG1λ monoclonal antibody that blocks the p19 subunit of IL-23, analyzing efficacy and safety data from phase I, II and III trials...
April 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29480455/ixekizumab-for-treating-moderate-to-severe-plaque-psoriasis-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#6
REVIEW
Bram L T Ramaekers, Robert F Wolff, Xavier Pouwels, Marije Oosterhoff, Anoukh Van Giessen, Gill Worthy, Caro Noake, Nigel Armstrong, Jos Kleijnen, Manuela A Joore
The National Institute for Health and Care Excellence invited Eli Lilly and Company Ltd, the company manufacturing ixekizumab (tradename Taltz® ), to submit evidence for the clinical and cost effectiveness of ixekizumab. Ixekizumab was compared with tumour necrosis factor-α inhibitors (etanercept, infliximab, adalimumab), ustekinumab, secukinumab, best supportive care and, if non-biological treatment or phototherapy is suitable, also compared with systemic non-biological therapies and phototherapy with ultraviolet B radiation for adults with moderate-to-severe plaque psoriasis...
February 26, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29464730/demyelination-during-anti-tumour-necrosis-factor-therapy-for-psoriasis
#7
J M E Boggs, L Barnes
Anti-tumour necrosis factor (anti-TNF) therapies have been associated with neurological complications, including in rare cases demyelinating disease. It is currently unknown whether patients who have received more than one immunosuppressive agent or anti-TNF have a greater risk of demyelination. We report the case of a 37-year-old woman with psoriasis who presented with an acute episode of demyelination while on anti-TNF therapy. This case was complicated by the fact that progressive multifocal leukoencephalopathy was considered the likely diagnosis initially and was only definitively excluded by brain biopsy...
February 21, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29398124/prevalence-and-incidence-of-psoriatic-arthritis-a-systematic-review-and-meta-analysis
#8
Lorenza Scotti, Matteo Franchi, Antonio Marchesoni, Giovanni Corrao
BACKGROUND: Psoriatic arthritis (PsA) is a specific form of inflammatory arthritis associated with psoriasis affecting in the same measure men and women but with a consistent geographic variability. Since the burden of PsA frequency has important implications in the definition of the healthcare policies, it is important to measure the frequency of disease in the general population. OBJECTIVE: To quantify the global health burden of PsA summarizing the data provided by the population-based available studies investigating prevalence and incidence of the disease...
January 6, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29318966/chronic-inflammatory-diseases-and-atherosclerotic-cardiovascular-disease-innocent-bystanders-or-partners-in-crime
#9
Peter Riis Hansen
Inflammation plays a significant role in atherosclerosis and cardiovascular disease (CVD). Patients with chronic inflammatory diseases are at increased risk of CVD, but it is debated whether this association is causal or dependent on shared risk factors, other exposures, genes, and/or inflammatory pathways. The current review summarizes epidemiological, clinical, and experimental data supporting the role of shared inflammatory mechanisms between atherosclerotic CVD and rheumatoid arthritis, psoriasis, inflammatory bowel disease, and periodontitis, respectively, and provides insights to future prospects in this area of research...
January 9, 2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29303139/temporomandibular-joint-involvement-in-psoriatic-arthritis
#10
Alime Okkesim, Mehmet Zahit Adisen, Melda Misirlioglu
Psoriasis is a chronic, papulosquamous, and an inflammatory skin disease. It has been found that between 5% and 24% of patients develop psoriatic arthritis (PA) at the same time after or even prior to skin findings. The involvement of temporomandibular joint (TMJ) is a rare condition. In this report, a-46-year-old male patient was referred to our clinic with the complaint of pain in the bilateral TMJs, and a limited jaw movement. Medical anamnesis revealed he had psoriasis for the last 21 years, and developed a seronegative polyarthritis with destructive changes for 8 years...
November 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/29295520/the-origin-of-skin-dendritic-cell-network-and-its-role-in-psoriasis
#11
REVIEW
Tae-Gyun Kim, Sung Hee Kim, Min-Geol Lee
Dendritic cells (DCs) are heterogeneous groups of innate immune cells, which orchestrate immune responses by presenting antigens to cognate T cells and stimulating other types of immune cells. Although the term 'DCs' generally represent highly mixed subsets with functional heterogeneity, the classical definition of DCs usually denotes conventional DCs (cDCs). Skin contains a unique DC network mainly composed of embryo precursor-derived epidermal Langerhans cells (LCs) and bone marrow-derived dermal cDCs, which can be further classified into type 1 (cDC1) and type 2 (cDC2) subsets...
December 23, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29226159/immunohistopathological-findings-of-severe-cutaneous-adverse-drug-reactions
#12
REVIEW
Mari Orime
Diagnosis of severe cutaneous adverse drug reactions should involve immunohistopathological examination, which gives insight into the pathomechanisms of these disorders. The characteristic histological findings of erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) provide conclusive evidence demonstrating that SJS/TEN can be distinguished from EM. Established SJS/TEN shows full-thickness, extensive keratinocyte necrosis that develops into subepidermal bullae. Drug-induced hypersensitivity syndrome (DIHS) and exanthema in drug reaction with eosinophilia and systemic symptoms (DRESS) each display a variety of histopathological findings, which may partly correlate with the clinical manifestations...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/29144382/treatment-approaches-to-moderate-to-severe-psoriasis
#13
REVIEW
Paolo Gisondi, Micol Del Giglio, Giampiero Girolomoni
Psoriasis is a common disease, which has a considerable impact on patients and the health care system. Treatment approaches to the disease may be various because some issues are not definitely addressed. Moreover, the therapeutic paradigms are continuously changing because of the recent approval of new treatments for psoriasis such as interleukin (IL)-17 inhibitors and apremilast. In this review, the factors influencing psoriasis severity, the indications for systemic treatments, the overall parameters to be considered in the treatment choice, life style interventions, and the recommendations for the use, screening, and monitoring of systemic therapies available including acitretin, cyclosporine, methotrexate, apremilast, adalimumab, etanercept, infliximab, secukinumab, ixekizumab, and ustekinumab are discussed...
November 16, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29142032/minimal-disease-activity-as-a-treatment-target-in-psoriatic-arthritis-a-review-of-the-literature
#14
REVIEW
Laure Gossec, Dennis McGonagle, Tatiana Korotaeva, Ennio Lubrano, Eugenio de Miguel, Mikkel Østergaard, Frank Behrens
As in other inflammatory rheumatic diseases, the objective of psoriatic arthritis (PsA) treatment is the achievement of a defined target. Recent recommendations propose aiming for remission or low disease activity; however, a consensual definition of remission is lacking. A state of minimal disease activity (MDA) has been established and is defined by low activity assessed by tender/swollen joint counts, tender entheseal points, Psoriasis Area and Severity Index or body surface area, patient pain and global activity visual analog scale, and functional evaluation by Health Assessment Questionnaire...
January 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29137492/a-guide-to-topical-vehicle-formulations
#15
Julia N Mayba, Melinda J Gooderham
Adherence to topical treatment for a variety of chronic skin conditions, such as psoriasis, acne, and atopic dermatitis, is known to be very poor. A number of factors contribute to this phenomenon, including lack of treatment efficacy and patient concerns regarding side effects, among others. At the forefront of barriers facing optimal patient adherence to topical treatment is choosing the ideal topical vehicle formulation. Medical professionals have demonstrated a lack of understanding with respect to the composition and nomenclature of the various topical formulations...
November 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29128966/is-the-dlqi-appropriate-for-medical-decision-making-in-psoriasis-patients
#16
Adrienn Katalin Poór, Valentin Brodszky, Márta Péntek, László Gulácsi, Gábor Ruzsa, Bernadett Hidvégi, Péter Holló, Sarolta Kárpáti, Miklós Sárdy, Fanni Rencz
Dermatology Life Quality Index (DLQI) is the most commonly applied measure of health-related quality of life (HRQoL) in psoriasis patients. It is among defining criteria of moderate-to-severe psoriasis and present in treatment guidelines. Our objective was to estimate preference-based HRQoL values (i.e., utilities) for hypothetical health states described by the 10 items of the DLQI in psoriasis patients. Moreover, we compare results to findings of a similar study previously conducted among the general public...
January 2018: Archives of Dermatological Research
https://www.readbyqxmd.com/read/29108826/physical-activity-and-autoimmune-diseases-get-moving-and-manage-the-disease
#17
REVIEW
Kassem Sharif, Abdulla Watad, Nicola Luigi Bragazzi, Micheal Lichtbroun, Howard Amital, Yehuda Shoenfeld
Physical activity, by definition, is any skeletal muscle body movement that results in energy expenditure. In the last few decades, a plethora of scientific evidences have accumulated and confirmed the beneficial role of physical activity as a modifiable risk factor for a wide variety of chronic diseases including cardiovascular diseases (CVDs), diabetes mellitus and cancer, among others. Autoimmune diseases are a heterogeneous group of chronic diseases, which occur secondary to loss of self-antigen tolerance...
January 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29106713/a-systematic-review-of-diagnostic-criteria-for-psoriasis-in-adults-and-children-evidence-from-studies-with-a-primary-aim-to-develop-or-validate-diagnostic-criteria
#18
REVIEW
E Burden-Teh, R C Phillips, K S Thomas, S Ratib, D Grindlay, R Murphy
BACKGROUND: The diagnosis of psoriasis in adults and children is made clinically, for both patient management and the selection of participants in research. Diagnostic criteria provide a structure for clinical assessment, which in turn helps standardize patient recruitment into clinical trials and case definitions in observational studies. OBJECTIVES: The aim of this systematic review was to identify and critically appraise the published studies to date that had a primary research aim to develop or validate diagnostic criteria for psoriasis...
November 6, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29080861/ideal-target-for-psoriatic-arthritis-comparison-of-remission-and-low-disease-activity-states-in-a-real-life-cohort
#19
Leonieke J J van Mens, Marleen G H van de Sande, Arno W R van Kuijk, Dominique Baeten, Laura C Coates
BACKGROUND: Psoriatic arthritis (PsA) recommendations state that the target of treatment should be remission or low disease activity (LDA). We used a real-life dataset to compare different potential targets. METHODS: 250 patients with PsA considered in an acceptable disease state according to their rheumatologist were included. Targets for remission were the Disease Activity Index for Psoriatic Arthritis (DAPSA) and clinical DAPSA (cDAPSA) remission (≤4), very low disease activity (VLDA) and Psoriatic Arthritis Disease Activity Score ≤1...
February 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29080318/koebner-s-sheep-in-wolf-s-clothing-does-the-isotopic-response-exist-as-a-distinct-phenomenon
#20
REVIEW
Rudolf Happle, Nicolas Kluger
Until 1995, a case of psoriasis developing within the dermatome of a healed herpes zoster was taken as a Koebner phenomenon. In this year, however, the term "isotopic response" was introduced by Wolf et al. to describe "the occurrence of a new skin disorder at the site of another, unrelated and already healed skin disease", thus appearing "on apparently unaffected and healthy skin." Initially, the term was mainly related to herpes zoster, but today the name "Wolf's isotopic response" is used to include a plethora of other triggering factors such as healed cutaneous leishmaniasis, tinea, or varicella...
October 28, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
110315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"